Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
Health Canada approved Sunshine Biopharma's Atenolol tablets in 25mg, 50mg, and 100mg dosages for the treatment of hypertension, angina, and post-myocardial infarction. The generic equivalent of Tenormin is expected to be ready for shipment to Canadian pharmacies by the end of 2026 through the company's subsidiary Nora Pharma.
Key figures
- Cagr
- 7.3%
- Drugs on market
- 60
- Atenolol market size 2025
- $12.45 billion
- Atenolol market size 2030
- $17.85 billion
- Canada global market share
- 2.1%
- Drugs launching remainder 2026
- approximately 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.